Abstract
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.
Highlights
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System
In the 8th edition of the AJCC, histologic grading, molecular subtype and multigene panels/genomic signatures were included into staging assessments
Whilst pathological and clinical stage remain a valuable aspect of the staging process and are strongly prognostic, we highlight here the evidence that supports Tumor Infiltrating Lymphocytes (TILs) as a biologic biomarker which improves discrimination over prognostic pathological and clinical staging for early stage triple-negative breast cancer (TNBC)
Summary
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System (www.cancerstaging. org). Prognostic biomarkers are becoming increasingly important given that many low early-stage breast cancer patients have excellent outcomes with standard of care treatments. These data were from 2148 patients enrolled onto eight prospective clinical trials as well as one large institutional cohort.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
